What Адельфан Treats: Main Uses and Benefits

The fixed-dose combination of Reserpine and Dihydralazine sulfate is utilized within cardiovascular medicine for the management of high blood pressure. This therapeutic approach is intended for the long-term management of this chronic condition.

This medication is applied in clinical settings involving consistently elevated arterial pressure, particularly when the condition is classified as moderate or severe. It is used for cases where blood pressure may not be adequately controlled by initial therapy, providing additional support for achieving management goals. The treatment assists during symptomatic periods by addressing physiological strain.

This combination is used for the management of essential hypertension, including instances of moderate to severe high blood pressure and situations where additional support is needed for sustained control.

“The primary intent is to support consistent pressure management over the long term, which assists with reducing the systemic burden.”

The treatment helps manage the physiological stress on the blood vessels, thereby supporting the reduction of long-term risks associated with uncontrolled high blood pressure. The medication serves as part of a management strategy to address cardiovascular complications linked to chronic hypertension.

---

Quick Fact: Supportive Management for Physiological Strain

Quick Fact: Supportive Management for Physiological Strain By assisting with pressure management, it helps maintain physiological stability when symptoms are present, which is relevant in conditions marked by increased vascular stress.

Regulatory References

1. Reserpine: MedlinePlus Drug Information

The eligibility for using Адельфан (Reserpine and Dihydralazine sulfate) is strictly defined by government regulatory labeling, which establishes specific conditions and populations where the medicine is either contraindicated or requires caution. The combination product inherits all restrictions from its two active components.

Populations for Whom Use is Prohibited (Contraindicated)

Contraindicated Condition	Component Basis
Mental depression or history of mental depression	Reserpine component
Active peptic ulcer or ulcerative colitis	Reserpine component
Systemic lupus erythematosus (SLE) and related diseases	Dihydralazine component
Severe tachycardia, Porphyria, or post-myocardial infarction stabilization phase not achieved	Dihydralazine component
Patients receiving Electroconvulsive Therapy (ECT)	Reserpine component

Restricted and Conditional Use

Official labeling requires specific caution or dose adjustments in other populations:

• Organ Impairment: Patients with severe renal impairment or hepatic impairment require dose adjustment. Use should be approached with caution in these conditions.
• Age Groups: The medicine is generally not established for and not recommended in the pediatric population. Use in older adults requires specific caution, particularly regarding the Reserpine dosage.
• Pregnancy and Lactation: Use should be avoided during the first and second trimesters of pregnancy. Use during lactation is generally not recommended.

Only adult patients without the documented contraindications are within the labeled eligibility scope for use in managing hypertension.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of the fixed-dose combination, Reserpine and Dihydralazine sulfate, through specific constraints and classifications of resulting effects.

Contraindicated Combinations and Required Separation

The co-administration of Адельфан with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This restriction extends to related agents: starting drugs like Deutetrabenazine or Tetrabenazine is contraindicated within a required minimum separation period of at least 20 days after stopping Reserpine.

Pharmacodynamic and Exposure Interactions

Combining this medicine with other antihypertensive agents (e.g., ACE inhibitors, diuretics) or CNS depressants may lead to additive hypotensive effects or increased central nervous system depression. The action of direct-acting sympathomimetics (e.g., Epinephrine) may be prolonged, while the action of indirect-acting sympathomimetics (e.g., Ephedrine) is officially inhibited by the Reserpine component. Conversely, the antihypertensive effect may be decreased when co-administered with substances such as Non-steroidal Anti-inflammatory Drugs (NSAIDs).

Food, Substance, and Special Population Considerations

The consumption of alcohol is explicitly discouraged, as it may potentiate the drug’s hypotensive or central depressant effects. Cautions are documented for co-administration with cardiac agents like Digitalis or Quinidine due to a documented risk of cardiac arrhythmias. Additionally, specific precautions are noted for use in patients with renal insufficiency.

Reduction of Sympathetic Tone via VMAT2 Inhibition

This domain focuses on the action of Reserpine, which acts as an irreversible inhibitor of the Vesicular Monoamine Transporter ( VMAT2) protein within sympathetic nerve endings . By blocking the storage of key neurotransmitters, primarily norepinephrine, the drug causes their depletion and lessens the nerve signal signaling for vasoconstriction. This molecular action leads to a sustained reduction in systemic sympathetic outflow.

Direct Relaxation of Arteriolar Smooth Muscle

The mechanism of Dihydralazine operates by directly modulating the intracellular calcium dynamics necessary for the contraction of arteriolar smooth muscle cells . By interfering with the availability of Ca^2+ in the vessel walls, the drug induces relaxation, which directly results in a reduction in peripheral vascular resistance (PVR), lowering the resistance against which blood flows.

Mechanistic Synergy and Baroreflex Blunting

The combination product engages a synergistic mechanism: the reduction in PVR caused by Dihydralazine typically triggers a compensatory sympathetic reflex. However, the action of Reserpine chemically ensures that the nerve terminals are functionally inert due to catecholamine depletion, thereby blunting the baroreflex. This critical interaction allows the vasodilation to be unopposed, contributing to the overall physiological effect of sustained PVR reduction.

How Адельфан is Used: Administration Guidelines

Адельфан, a fixed-dose combination containing Reserpine and Dihydralazine sulfate, is used for the chronic management of high blood pressure and is administered via the oral route in tablet form.

Dosage and Schedule

Treatment is initiated based on a dose that is individually determined for the patient through titration of the individual components. The fixed-dose combination itself is generally not intended for initial therapy. The standard adult regimen involves a maintenance dose of one to two tablets per day, taken in divided doses, typically twice daily. The maximum dose for the Reserpine component is typically limited to 0.25 mg per day.

Administration Conditions and Adjustments

For proper administration, tablets are taken consistently with respect to meals to support reliable absorption of the Dihydralazine component. The combination is intended for long-term use in chronic conditions.

Dosage is adapted for patients with documented impaired kidney or liver function to prevent accumulation of the components. Furthermore, while there is no specific starting dose for older adults, the dose is adjusted considering that kidney function commonly diminishes with age.

Summary of Procedural Use

This regimen is procedural, requiring the dose to be established beforehand through individual assessment. Once established, the schedule typically involves a twice-daily oral intake, maintaining consistency around meal times. Clinical assessment includes consideration of underlying renal or hepatic function during the course of therapy.

Research Evidence / Overview of Studies for Адельфан

This section provides an objective overview of the clinical research and scientific studies that have evaluated the fixed-dose combination of Reserpine and Dihydralazine sulfate (Адельфан), focusing only on the structure of the evidence and areas of certainty and uncertainty.

---

Evidence for Use in Essential Hypertension

Research has studied this combination for essential hypertension (high blood pressure). The evidence base includes a mix of historical Randomized Controlled Trials (RCTs) and long-term open-label surveillance studies. The RCTs primarily explored the effects of the individual components in studies exploring changes in blood pressure measurements.

In these studies, researchers monitored outcomes related to systemic or functional imbalance, specifically focusing on measured changes in systolic and diastolic blood pressure (SBP and DBP). Findings describe patterns observed in the studies where initial pressure measurements reported measured changes from baseline levels following treatment initiation.

---

Durability and Long-Term Follow-up Data

Studies of the fixed-dose combination have included long-term follow-up durations that was observed in surveillance studies lasting up to three years (36 months). These studies research examined temporary physiological imbalance over defined time intervals. Long-term settings evidence contributes to understanding symptom patterns over time in patients monitoring blood pressure patterns.

While these extended open-label studies research describes the stability of pressure measurements within the studied population, the long-term effects are not fully established regarding the drug's influence on major cardiovascular health events like heart attack or stroke. The certainty remains low for inferring such hard outcomes from the available data on this specific fixed-dose drug.

---

Evidence Gaps and Areas of Uncertainty

The research landscape contains several identified gaps. The primary limitation is the lack of modern, large-scale Randomized Controlled Trials (RCTs) that directly compare the fixed-dose combination against current standard-of-care antihypertensive drugs. This means comparative evidence is lacking for many contemporary clinical questions. Additionally, the follow-up durations were limited in many of the older controlled trials, which means that there is limited information for long-term outcomes regarding the reduction of cardiovascular events.

Key Studies & References Reserpine: MedlinePlus Drug Information (National Library of Medicine)

Common questions about Адельфан (FAQ)

Q: Why do some people refer to Адельфан as a 'high blood pressure' medication?

According to regulatory documents, the medicine is officially classified as an antihypertensive agent. Its general purpose is the long-term management of elevated blood pressure, which is commonly referred to as hypertension.

Q: Is there a known withdrawal period associated with stopping Адельфан?

Official information indicates that effects from the Reserpine component, including effects on the cardiovascular and central nervous systems, may persist for a period of time after the medicine is discontinued. Changes to a drug regimen should only be made under the guidance of a healthcare professional.

Q: What makes Адельфан different from other single-ingredient blood pressure medicines?

This medicine is a fixed-dose combination containing two active ingredients. It combines Reserpine, an agent that reduces nerve signals for vasoconstriction, and Dihydralazine sulfate, which directly relaxes the blood vessels. This dual mechanism is described in official documents as addressing the nervous system and peripheral circulation.

Q: Does Адельфан have a known effect on sleep patterns?

The Reserpine component has been associated with effects on the nervous system. These documented side effects may include reports of drowsiness, vivid dreams or nightmares, and early-morning sleeplessness.

Q: Can I take other types of blood pressure medication along with Адельфан?

Combining this medicine with other agents used for high blood pressure (antihypertensives) is described in official documents as potentially leading to an additive blood pressure lowering effect. Official guidance indicates that caution and close monitoring are necessary when combining this medicine with other antihypertensive agents.

Q: Can Адельфан be used during pregnancy or while breastfeeding?

The use of this medicine should be officially avoided during the first and second trimesters of pregnancy. Furthermore, its use is generally not recommended during the period of lactation.

Q: What is the general duration of action for a single dose of Адельфан?

This medicine is intended for the chronic management of blood pressure. To maintain a sustained effect, the regimen is typically prescribed to be taken in divided doses to maintain a sustained effect for the chronic management of blood pressure.

Q: Can Адельфан be taken by older patients?

Official information confirms that use in older adults requires specific caution. The dosage may need adjustment, particularly concerning the Reserpine component, due to common changes in organ function with age.

Q: Do studies support the long-term use of Адельфан for its intended purpose?

Research on this combination has included long-term follow-up and surveillance studies, which have focused on the stability of blood pressure measurements over time. Official documents indicate that the long-term effects on major cardiovascular events, such as heart attack or stroke, are not fully established from the available data.

Q: Is it normal to feel a bit dizzy when first starting Адельфан?

Dizziness, especially when changing body position, is described in official documentation as a common effect associated with related combination products. This can be an effect observed early in treatment, which may be related to the blood pressure lowering effect.

Q: Is Адельфан a diuretic or does it contain one?

This medicine is a combination of a centrally acting antiadrenergic agent (Reserpine) and an arteriolar vasodilator (Dihydralazine). It does not contain a diuretic component.

Q: Can I take Адельфан if I am also taking medicine for pain relief?

Co-administration with certain pain relief medicines, particularly those classified as Central Nervous System (CNS) depressants (like certain opioid analgesics), may enhance the CNS depressant or blood pressure lowering effects of this drug. This possible interaction is noted in official documents as requiring specific consideration.

Q: What happens if a patient misses a scheduled dose of Адельфан?

Regulatory guidance for related products contains specific advice on how to proceed with a missed dose to avoid taking an excessive amount close to the next scheduled time. The full instructions for a missed dose can be found in the official product information.

Q: Are there any specific organs that Адельфан is known to affect?

Official labeling documents adverse effects across several body systems, including the Cardiac, Vascular, Nervous System, and Blood and Lymphatic systems. Furthermore, caution is noted for patients with documented impaired kidney or liver function.

Q: Is Адельфан considered a 'first-line' treatment option?

Official documentation states that this fixed-dose combination is generally not intended for initial therapy for high blood pressure. It is typically used after initial treatment methods have been established or in situations where combined therapy is considered.

Q: Is there a maximum length of time a person is generally expected to take Адельфан?

This medicine is specifically intended for the long-term use and chronic management of high blood pressure. Official documents do not specify a maximum length of time or a requirement to stop continuous use.

Q: Why are there warnings about suddenly stopping certain types of blood pressure drugs like this one?

The sudden discontinuation of certain blood pressure agents can lead to a rapid or significant increase in blood pressure, known as a rebound effect. This potential for increased pressure is the reason why abrupt changes to the medication are strongly cautioned against.

Q: Can people with a history of stomach ulcers take Адельфан?

Official labeling contraindicates use in patients who have an active peptic ulcer or ulcerative colitis. Caution is also advised for those with a history of these conditions due to the risk of reactivation associated with the Reserpine component.

Q: What are the considerations for patients who drive or operate machinery while using Адельфан?

Because the medicine may cause effects such as drowsiness, dizziness, or dull sensorium (a state of reduced awareness), caution is recommended when performing activities that require full mental alertness, such as driving or operating machinery.

The official regulatory requirements for storing and disposing of Адельфан (Reserpine and Dihydralazine sulfate combination tablets) are defined to ensure product stability and safety.

Storage Requirements

• Temperature: Store at Controlled Room Temperature (CRT), typically between 20 C to 25 C (68 F to 77 F).
• Protection: The medicine must be protected from moisture, excessive heat, and light, and explicitly must not freeze.
• Container: Keep the product in its original container and ensure the container remains tightly closed.
• Child Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

• Wastewater: The official label advises not to flush the medicine down the toilet or drain.
• Discarding: Unused or expired medication should be disposed of through a dedicated drug take-back program or an authorized pharmaceutical waste collector, following local and national regulations.